Immunoglobulin Replacement Therapy for Immunoglobulin G Subclass 2 Deficient Patients With Bronchiectasis
Status:
Withdrawn
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
Bronchiectasis is a common chronic lung condition where patients have permanent airways
damage leading to daily symptoms of cough, sputum production and recurrent respiratory tract
infections.
Preliminary studies in our research group have found a severe deficiency of the immune system
as a rare cause of bronchiectasis (called immunoglobulin G subclass 2 deficiency) and occurs
in about 1 in 20 bronchiectasis patients. The pilot work shows that these patients have more
chest infections and their lung function deteriorates more rapidly.
There are no trials to date to guide doctors to decide whether we should replace this
deficiency from donated blood or not. The aim with treatment is to prevent disease
progression and avoid the need for long term antibiotics.
This trial will help us understand how this treatment works and its acceptability to
patients. This study will help us decide whether investigators should pursue future
formalised trials in many centres throughout the UK and how investigators should evaluate
such a treatment.
We are looking to recruit 20 patients to this study 10 of which will receive weekly
replacement therapy and the remaining 10 will receive standard care.